MOTS-c (Human) MS
Mitochondrial-derived peptide
Mitochondrial-derived 16-amino-acid peptide from the 12S rRNA gene, studied for folate-cycle inhibition, AMPK activation and muscle metabolism.
Evidence level. Evidence comes mainly from animal or other preclinical models. About the badges
- Class
- Mitochondrial-derived peptide
- Category
- Mitochondrial & Longevity
- Type
- Single compound
- Abbreviation
- MS
- Development and regulatory status
- Not approved; preclinical research peptide
What researchers study
16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. In cells it inhibits the folate cycle and de novo purine synthesis, leading to AMPK activation; skeletal muscle appears to be its primary target organ.
Research areas
- AMPK signalling and metabolic homeostasis
- Insulin sensitivity in diet-induced obesity mice
- Exercise capacity and muscle metabolism in mice
- Mitochondrial-to-nuclear signalling
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- rodent
MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance as well as diet-induced obesity
- rodent
MOTS-c enhanced physical performance in young, middle-aged and old mice, and in humans exercise raised endogenous MOTS-c in muscle and blood
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- AICARAnother AMPK-pathway activator studied in metabolic and exercise-mimetic models
- SS-31Mitochondria-focused peptide studied in ageing and energy-metabolism research
- NAD+ + MOTS-c + 5-Amino-1MQCatalogue longevity blend containing MOTS-c
- 5-Amino-1MQNNMT inhibitor studied in metabolic models alongside MOTS-c
